You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDiethylpropion
Accession NumberDB00937  (APRD00919)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)
Structure
Thumb
Synonyms
(+-)-Diethylpropion
(±)-diethylpropion
1-phenyl-2-diethylamino-1-propanone
2-(Diethylamino)-1-phenyl-1-propanone
2-(Diethylamino)propiophenone
alpha-Benzoyltriethylamine
alpha-Diethylaminopropiophenone
Amfepramone
Amfepramonum
Anfepramona
Diethylcathinone
Diethylpropion
External Identifiers
  • DEA No. 1610
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Diethylpropion HCl Controlled-releaseTablet75 mg/1OralActavis Pharma, Inc.1960-11-17Not applicableUs
Diethylpropion HCl Controlled-releaseTablet75 mg/1OralPhysicians Total Care, Inc.2005-10-03Not applicableUs
Diethylpropion HCl Controlled-releaseTablet75 mg/1OralPreferred Pharmaceuticals, Inc.2014-02-12Not applicableUs
Diethylpropion HCl Controlled-releaseTablet75 mg/1OralA S Medication Solutions Llc1960-11-17Not applicableUs
Diethylpropion HCl Controlled-releaseTablet75 mg/1OralNu Care Pharmaceuticals, Inc.1960-11-17Not applicableUs
Diethylpropion HCl Controlled-releaseTablet75 mg/1OralRebel Distributors Corp2008-01-01Not applicableUs
Diethylpropion HCl Controlled-releaseTablet75 mg/1Oralbryant ranch prepack2008-01-01Not applicableUs
Diethylpropion HCl Controlled-releaseTablet75 mg/1OralA S Medication Solutions Llc1960-11-17Not applicableUs
Diethylpropion HCl Immediate-releaseTablet25 mg/1OralPhysicians Total Care, Inc.2004-06-14Not applicableUs
Diethylpropion HCl Immediate-releaseTablet25 mg/1Oralbryant ranch prepack2008-01-01Not applicableUs
Diethylpropion HCl Immediate-releaseTablet25 mg/1OralA S Medication Solutions Llc1959-08-06Not applicableUs
Diethylpropion HCl Immediate-releaseTablet25 mg/1OralNu Care Pharmaceuticals, Inc.1959-08-06Not applicableUs
Diethylpropion HCl Immediate-releaseTablet25 mg/1OralActavis Pharma, Inc.1959-08-06Not applicableUs
Diethylpropion HCl Immediate-releaseTablet25 mg/1OralA S Medication Solutions Llc1959-08-06Not applicableUs
Diethylpropion Hydrochloride Controlled-releaseTablet75 mg/1OralPd Rx Pharmaceuticals, Inc.2008-01-01Not applicableUs
Nobesine 75 Sustained Release Capsule 75mgCapsule, extended release75 mgOralRougier Pharma Division Of Ratiopharm Inc1978-12-311999-09-27Canada
TenuateTablet25 mgOralSanofi Aventis Canada Inc1994-12-312009-03-24Canada
Tenuate DospanTablet, extended release75 mgOralSanofi Aventis Canada Inc1994-12-312009-01-31Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Diethylpropion HCl Controlled-releaseTablet75 mg/1OralKeltman Pharmaceuticals Inc.2010-06-07Not applicableUs
Diethylpropion HCl Controlled-releaseTablet75 mg/1OralBlenheim Pharmacal, Inc.2010-03-30Not applicableUs
Diethylpropion HCl Immediate-releaseTablet25 mg/1OralKeltman Pharmaceuticals Inc.2010-06-07Not applicableUs
Diethylpropion HCl Immediate-releaseTablet25 mg/1OralPd Rx Pharmaceuticals, Inc.2008-01-01Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralLannett Company, Inc.2011-07-18Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralA S Medication Solutions Llc2010-12-27Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralApotheca Inc1999-08-16Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralPd Rx Pharmaceuticals, Inc.2010-12-27Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralUnit Dose Services2010-12-27Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralAidarex Pharmaceuticals LLC2010-12-27Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralKvk Tech, Inc2010-12-27Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralCorepharma LLC.2008-11-062016-03-16Us
Diethylpropion Hydrochloride ERTablet, extended release75 mg/1OralLannett Company, Inc.2011-10-24Not applicableUs
Diethylpropion Hydrochloride ERTablet75 mg/1OralApotheca Inc2008-10-23Not applicableUs
Diethylpropion Hydrochloride ERTablet, extended release75 mg/1OralPd Rx Pharmaceuticals, Inc.2011-10-24Not applicableUs
Diethylpropion Hydrochloride ERTablet, extended release75 mg/1OralPreferred Pharmaceuticals, Inc.2014-04-29Not applicableUs
Diethylpropion Hydrochloride ERTablet, extended release75 mg/1OralA S Medication Solutions Llc2011-10-24Not applicableUs
Diethylpropion Hydrochloride ERTablet, extended release75 mg/1OralProficient Rx LP2011-10-24Not applicableUs
Diethylpropion Hydrochlorideer ERTablet, extended release75 mg/1OralAidarex Pharmaceuticals LLC2011-10-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnorexNot Available
DobesinNot Available
FrekentineNot Available
LineaNot Available
ModeratanNot Available
NeobesMedix
NobesineNot Available
PrefamoneNot Available
RegenonTemmler
TepanilNot Available
TylinalNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Diethylpropion Hydrochloride
134-80-5
Thumb
  • InChI Key: ICFXZZFWRWNZMA-UHFFFAOYNA-N
  • Monoisotopic Mass: 241.123341974
  • Average Mass: 241.757
DBSALT000484
Categories
UNIIQ94YYU22B8
CAS number90-84-6
WeightAverage: 205.2961
Monoisotopic: 205.146664235
Chemical FormulaC13H19NO
InChI KeyXXEPPPIWZFICOJ-UHFFFAOYSA-N
InChI
InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3
IUPAC Name
2-(diethylamino)-1-phenylpropan-1-one
SMILES
CCN(CC)C(C)C(=O)C1=CC=CC=C1
Pharmacology
IndicationUsed in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.
Structured Indications
PharmacodynamicsDiethylpropion is a sympathomimetic stimulant drug marketed as an appetite suppressant. Chemically, it is the N,N-diethyl analog of cathinone. Its mechanism of action is similar to other appetite suppressants such as sibutramine, phentermine and dextroamphetamine.
Mechanism of actionDiethylpropion is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. Diethylpropion (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that diethylpropion can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Sodium-dependent dopamine transporterProteinyes
inhibitor
HumanQ01959 details
Related Articles
AbsorptionDiethylpropion is rapidly absorbed from the GI tract after oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Many of these metabolites are biologically active and may participate in the therapeutic action of diethylpropion.

Route of eliminationDiethylpropion is rapidly absorbed from the GI tract after oral administration and is extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Diethylpropion and/or its active metabolites are believed to cross the blood-brain barrier and the placenta. Diethylpropion and its metabolites are excreted mainly by the kidney.
Half lifeUsing a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours.
ClearanceNot Available
ToxicityThe reported oral LD50 for mice is 600 mg/kg, for rats is 250 mg/kg and for dogs is 225 mg/kg. Manifestation of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Diethylpropion.Experimental
AcepromazineAcepromazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Diethylpropion.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Diethylpropion.Approved
AcrivastineDiethylpropion may decrease the sedative activities of Acrivastine.Approved
AlcaftadineDiethylpropion may decrease the sedative activities of Alcaftadine.Approved
AlfentanilDiethylpropion may increase the analgesic activities of Alfentanil.Approved, Illicit
AlimemazineDiethylpropion may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlphacetylmethadolDiethylpropion may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
Aluminum phosphateAluminum phosphate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of Diethylpropion.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of Diethylpropion.Approved
Ammonium chlorideThe serum concentration of Diethylpropion can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Diethylpropion.Experimental
AntazolineDiethylpropion may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of Diethylpropion.Approved
AstemizoleDiethylpropion may decrease the sedative activities of Astemizole.Approved, Withdrawn
AzaperoneAzaperone may decrease the stimulatory activities of Diethylpropion.Vet Approved
AzatadineDiethylpropion may decrease the sedative activities of Azatadine.Approved
AzelastineDiethylpropion may decrease the sedative activities of Azelastine.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Diethylpropion.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Diethylpropion.Investigational
BezitramideDiethylpropion may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Diethylpropion.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Diethylpropion.Approved
BromperidolBromperidol may decrease the stimulatory activities of Diethylpropion.Investigational
BrompheniramineDiethylpropion may decrease the sedative activities of Brompheniramine.Approved
BuclizineDiethylpropion may decrease the sedative activities of Buclizine.Approved
BuprenorphineDiethylpropion may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
Butanoic AcidDiethylpropion may decrease the sedative activities of Butanoic Acid.Experimental
ButorphanolDiethylpropion may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Calcium carbonateCalcium carbonate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
CarbinoxamineDiethylpropion may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilDiethylpropion may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Diethylpropion.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Diethylpropion.Withdrawn
CetirizineDiethylpropion may decrease the sedative activities of Cetirizine.Approved
ChloropyramineDiethylpropion may decrease the sedative activities of Chloropyramine.Approved
ChlorphenamineDiethylpropion may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineDiethylpropion may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Diethylpropion.Approved, Withdrawn
CimetidineDiethylpropion may decrease the sedative activities of Cimetidine.Approved
CinnarizineDiethylpropion may decrease the sedative activities of Cinnarizine.Approved
ClemastineDiethylpropion may decrease the sedative activities of Clemastine.Approved
ClomipramineClomipramine may increase the stimulatory activities of Diethylpropion.Approved, Vet Approved
ClozapineClozapine may decrease the stimulatory activities of Diethylpropion.Approved
CodeineDiethylpropion may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Diethylpropion.Approved
CyclizineDiethylpropion may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Diethylpropion.Approved
CyproheptadineDiethylpropion may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Diethylpropion.Approved
DesipramineDesipramine may increase the stimulatory activities of Diethylpropion.Approved
DesloratadineDiethylpropion may decrease the sedative activities of Desloratadine.Approved, Investigational
DexbrompheniramineDiethylpropion may decrease the sedative activities of Dexbrompheniramine.Approved
Dexchlorpheniramine maleateDiethylpropion may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramideDiethylpropion may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneDiethylpropion may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineDiethylpropion may increase the analgesic activities of Dezocine.Approved
DiclofenamideDiclofenamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
DihydrocodeineDiethylpropion may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineDiethylpropion may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineDiethylpropion may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateDiethylpropion may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneDiethylpropion may decrease the sedative activities of Dimetindene.Approved
DimetotiazineDiethylpropion may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineDiethylpropion may decrease the sedative activities of Diphenhydramine.Approved
DiphenoxylateDiethylpropion may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DosulepinDosulepin may increase the stimulatory activities of Diethylpropion.Approved
DoxepinDiethylpropion may decrease the sedative activities of Doxepin.Approved
DoxylamineDiethylpropion may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEDiethylpropion may increase the analgesic activities of DPDPE.Investigational
DroperidolDroperidol may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
EbastineDiethylpropion may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Diethylpropion.Investigational
EmedastineDiethylpropion may decrease the sedative activities of Emedastine.Approved
EpinastineDiethylpropion may decrease the sedative activities of Epinastine.Approved, Investigational
EsmirtazapineDiethylpropion may decrease the sedative activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Diethylpropion.Approved
EthopropazineDiethylpropion may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Diethylpropion.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Withdrawn
EthylmorphineDiethylpropion may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtorphineDiethylpropion may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineDiethylpropion may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit, Withdrawn
FentanylDiethylpropion may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineDiethylpropion may decrease the sedative activities of Fexofenadine.Approved
FlunarizineDiethylpropion may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Diethylpropion.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Diethylpropion.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Diethylpropion.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of Diethylpropion.Approved, Vet Approved
GuanethidineThe serum concentration of Diethylpropion can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Diethylpropion.Approved
HeroinDiethylpropion may increase the analgesic activities of Heroin.Approved, Illicit
HexamethylenetetramineThe serum concentration of Diethylpropion can be decreased when it is combined with Hexamethylenetetramine.Approved, Vet Approved
HydracarbazineHydracarbazine may increase the hypertensive activities of Diethylpropion.Approved
HydrocodoneDiethylpropion may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneDiethylpropion may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydroxyzineDiethylpropion may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Diethylpropion.Approved
ImipramineImipramine may increase the stimulatory activities of Diethylpropion.Approved
Ioflupane I-123Diethylpropion may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the hypertensive activities of Diethylpropion.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Diethylpropion.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Diethylpropion.Approved
IsothipendylDiethylpropion may decrease the sedative activities of Isothipendyl.Approved
Kct 0809Diethylpropion may decrease the sedative activities of Kct 0809.Investigational
KetobemidoneDiethylpropion may increase the analgesic activities of Ketobemidone.Approved
KetotifenDiethylpropion may decrease the sedative activities of Ketotifen.Approved
L-Glutamic AcidThe serum concentration of Diethylpropion can be decreased when it is combined with L-Glutamic Acid.Nutraceutical
LevocabastineDiethylpropion may decrease the sedative activities of Levocabastine.Approved
LevocetirizineDiethylpropion may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateDiethylpropion may increase the analgesic activities of Levomethadyl Acetate.Approved
LevorphanolDiethylpropion may increase the analgesic activities of Levorphanol.Approved
LithiumLithium may decrease the stimulatory activities of Diethylpropion.Approved
LodoxamideDiethylpropion may decrease the sedative activities of Lodoxamide.Approved
LofentanilDiethylpropion may increase the analgesic activities of Lofentanil.Illicit
LoratadineDiethylpropion may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of Diethylpropion.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Diethylpropion.Approved
MagaldrateMagaldrate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Withdrawn
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Diethylpropion.Withdrawn
MeclizineDiethylpropion may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of Diethylpropion.Approved
MepyramineDiethylpropion may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineDiethylpropion may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Diethylpropion.Approved
MethadoneDiethylpropion may increase the analgesic activities of Methadone.Approved
Methadyl AcetateDiethylpropion may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethapyrileneDiethylpropion may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Diethylpropion.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Diethylpropion.Investigational
MetiamideDiethylpropion may decrease the sedative activities of Metiamide.Experimental
MianserinDiethylpropion may decrease the sedative activities of Mianserin.Approved
MinaprineMinaprine may increase the hypertensive activities of Diethylpropion.Approved
MirtazapineDiethylpropion may decrease the sedative activities of Mirtazapine.Approved
MizolastineDiethylpropion may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Diethylpropion.Approved
MolindoneMolindone may decrease the stimulatory activities of Diethylpropion.Approved
MorphineDiethylpropion may increase the analgesic activities of Morphine.Approved, Investigational
NalbuphineDiethylpropion may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of Diethylpropion.Withdrawn
NizatidineDiethylpropion may decrease the sedative activities of Nizatidine.Approved
NormethadoneDiethylpropion may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of Diethylpropion.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Diethylpropion.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
OlopatadineDiethylpropion may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Diethylpropion.Approved
OpipramolOpipramol may increase the stimulatory activities of Diethylpropion.Investigational
OpiumDiethylpropion may increase the analgesic activities of Opium.Approved, Illicit
OsanetantOsanetant may decrease the stimulatory activities of Diethylpropion.Investigational
OxycodoneDiethylpropion may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneDiethylpropion may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may decrease the stimulatory activities of Diethylpropion.Approved
PargylinePargyline may increase the hypertensive activities of Diethylpropion.Approved
PemirolastDiethylpropion may decrease the sedative activities of Pemirolast.Approved
PentazocineDiethylpropion may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Diethylpropion.Investigational
PerospironePerospirone may decrease the stimulatory activities of Diethylpropion.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Diethylpropion.Approved
PethidineDiethylpropion may increase the analgesic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Diethylpropion.Approved
PhenindamineDiethylpropion may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Diethylpropion.Withdrawn
PheniramineDiethylpropion may decrease the sedative activities of Pheniramine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Diethylpropion.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Diethylpropion.Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Diethylpropion.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Diethylpropion.Approved
PipamperonePipamperone may decrease the stimulatory activities of Diethylpropion.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of Diethylpropion.Approved
PiritramideDiethylpropion may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Diethylpropion.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Diethylpropion.Withdrawn
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
PromethazineDiethylpropion may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Diethylpropion.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of Diethylpropion.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of Diethylpropion.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Diethylpropion.Approved
RacloprideRaclopride may decrease the stimulatory activities of Diethylpropion.Investigational
RanitidineDiethylpropion may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of Diethylpropion.Approved
RemifentanilDiethylpropion may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Diethylpropion.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Diethylpropion.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Diethylpropion.Investigational
Roxatidine acetateDiethylpropion may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of Diethylpropion.Withdrawn
SelegilineSelegiline may increase the hypertensive activities of Diethylpropion.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Diethylpropion.Approved, Withdrawn
Spaglumic AcidDiethylpropion may decrease the sedative activities of Spaglumic Acid.Approved
SufentanilDiethylpropion may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Diethylpropion.Approved
TapentadolDiethylpropion may increase the analgesic activities of Tapentadol.Approved
TerfenadineDiethylpropion may decrease the sedative activities of Terfenadine.Withdrawn
TesmilifeneDiethylpropion may decrease the sedative activities of Tesmilifene.Investigational
ThioproperazineThioproperazine may decrease the stimulatory activities of Diethylpropion.Approved
ThioridazineThioridazine may decrease the stimulatory activities of Diethylpropion.Approved
ThiothixeneThiothixene may decrease the stimulatory activities of Diethylpropion.Approved
ThonzylamineDiethylpropion may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of Diethylpropion.Approved
TiaprideTiapride may decrease the stimulatory activities of Diethylpropion.Investigational
ToloxatoneToloxatone may increase the hypertensive activities of Diethylpropion.Approved
TramadolDiethylpropion may increase the analgesic activities of Tramadol.Approved, Investigational
TranilastDiethylpropion may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Diethylpropion.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Diethylpropion.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Diethylpropion.Approved
TriflupromazineTriflupromazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of Diethylpropion.Approved
TripelennamineDiethylpropion may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineDiethylpropion may decrease the sedative activities of Triprolidine.Approved
Vitamin CThe serum concentration of Diethylpropion can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of Diethylpropion.Approved
ZotepineZotepine may decrease the stimulatory activities of Diethylpropion.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Schutte, J.; U.S. Patent 3,001,910; September 26, 1961; assigned to Firma Ternmler-Werke
(W. Germany).

US3001910
General References
  1. Adan RA, Vanderschuren LJ, la Fleur SE: Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17. doi: 10.1016/j.tips.2008.01.008. Epub 2008 Mar 18. [PubMed:18353447 ]
  2. Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. doi: 10.1016/S0074-7742(09)88009-4. [PubMed:19897080 ]
External Links
ATC CodesA08AA03
AHFS Codes
  • 28:20.92
PDB EntriesNot Available
FDA labelDownload (114 KB)
MSDSDownload (103 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9354
Caco-2 permeable+0.8532
P-glycoprotein substrateNon-substrate0.5328
P-glycoprotein inhibitor INon-inhibitor0.8859
P-glycoprotein inhibitor IINon-inhibitor0.9157
Renal organic cation transporterNon-inhibitor0.6691
CYP450 2C9 substrateNon-substrate0.8022
CYP450 2D6 substrateNon-substrate0.6551
CYP450 3A4 substrateNon-substrate0.6339
CYP450 1A2 substrateInhibitor0.7358
CYP450 2C9 inhibitorNon-inhibitor0.952
CYP450 2D6 inhibitorNon-inhibitor0.7815
CYP450 2C19 inhibitorNon-inhibitor0.8088
CYP450 3A4 inhibitorNon-inhibitor0.9438
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6602
Ames testNon AMES toxic0.9326
CarcinogenicityCarcinogens 0.5877
BiodegradationNot ready biodegradable0.9236
Rat acute toxicity2.6791 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8475
hERG inhibition (predictor II)Non-inhibitor0.8179
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Watson pharmaceuticals
  • 3m pharmaceuticals inc
  • Corepharma llc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Tg united labs llc
  • Ucb inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral75 mg/1
TabletOral25 mg/1
Tablet, extended releaseOral75 mg/1
Capsule, extended releaseOral75 mg
TabletOral25 mg
Tablet, extended releaseOral75 mg
Prices
Unit descriptionCostUnit
Diethylpropion HCl CR 75 mg 24 Hour tablet1.0USD tablet
Tenuate 25 mg tablet0.67USD tablet
Diethylpropion 25 mg tablet0.52USD tablet
Diethylpropion HCl 25 mg tablet0.29USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point168Schutte, J.; U.S. Patent 3,001,910; September 26, 1961; assigned to Firma Ternmler-Werke (W. Germany).
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.22 mg/mLALOGPS
logP2.8ALOGPS
logP2.7ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)17.43ChemAxon
pKa (Strongest Basic)7.44ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity63.88 m3·mol-1ChemAxon
Polarizability24.12 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0udi-2900000000-43214c102b76f59ba4d1View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acetophenones. These are organic compounds containing the acetophenone structure.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAcetophenones
Direct ParentAcetophenones
Alternative Parents
Substituents
  • Phenylpropane
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Benzoyl
  • Alpha-aminoketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. doi: 10.1016/S0074-7742(09)88009-4. [PubMed:19897080 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Yu H, Rothman RB, Dersch CM, Partilla JS, Rice KC: Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. Bioorg Med Chem. 2000 Dec;8(12):2689-92. [PubMed:11131159 ]
  2. Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. doi: 10.1016/S0074-7742(09)88009-4. [PubMed:19897080 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23